https://affinittx.com/affini-t-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/ 2023-01-05T08:00:55-05:00 https://affinittx.com/the-endpoints-11-the-top-private-biotechs-in-pursuit-of-new-drugs-pushing-the-envelope-with-powerful-new-technologies/ 2022-12-19T11:59:54-05:00 https://affinittx.com/elevatebio-and-affini-t-therapeutics-announce-partnership-to-advance-affini-ts-t-cell-therapy-programs-targeting-core-oncogenic-drivers/ 2022-11-15T07:27:30-05:00 https://affinittx.com/society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting-2022/ 2022-11-10T09:00:31-05:00 https://affinittx.com/society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting-2022-afnt-211/ 2022-11-10T08:59:36-05:00 https://affinittx.com/affini-t-therapeutics-to-present-preclinical-data-from-its-lead-programs-targeting-kras-g12v-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting/ 2022-11-07T05:58:51-05:00 https://affinittx.com/affini-t-therapeutics-appoints-pioneering-t-cell-therapy-and-kras-developer-dirk-nagorsen-m-d-as-chief-medical-officer/ 2022-09-22T09:43:58-04:00 https://affinittx.com/affini-t-therapeutics-named-to-the-2022-endpoints-11/ 2022-09-22T09:42:13-04:00 https://affinittx.com/corporate-deck-for-affini-t-therapeutics-inc-at-40th-annual-j-p-morgan-healthcare-conference/ 2022-08-05T19:59:53-04:00 https://affinittx.com/go-quickly-amgen-rd-vet-dirk-nagorsen-jumps-to-a-startup-with-big-plans-for-tcrs/ 2022-08-03T19:35:05-04:00 https://affinittx.com/meet-the-23-biotech-startups-that-are-set-to-take-off-in-the-next-12-months-according-to-top-vcs/ 2022-08-03T19:34:23-04:00 https://affinittx.com/no-introductions-necessary-a-tcr-upstart-with-deep-pocket-backers-partners-with-one-of-the-new-players-in-the-hot-gene-editing-field/ 2022-08-03T12:12:10-04:00 https://affinittx.com/affini-t-therapeutics-appoints-jill-desimone-to-its-board-of-directors/ 2022-07-12T08:16:26-04:00 https://affinittx.com/affini-t-therapeutics-metagenomi-announce-next-generation-gene-editing-partnership-to-advance-cell-therapies-for-solid-tumor-patients/ 2022-06-15T10:21:06-04:00 https://affinittx.com/affini-t-therapeutics-kras-tcr-t-cell-therapy-program-to-be-presented-at-the-annual-meeting-of-the-american-society-of-gene-and-cell-therapy/ 2022-06-08T12:40:43-04:00 https://affinittx.com/affini-t-therapeutics-to-present-at-upcoming-investor-and-industry-conferences/ 2022-06-08T11:47:26-04:00 https://affinittx.com/clinical-strategy-for-enhancing-affini-t-therapeutics-merkel-polyoma-virus-tcr-therapy-to-be-presented-at-asco-2022/ 2022-06-02T08:00:09-04:00 https://affinittx.com/affini-t-expands-board-of-directors-with-appointments-of-michael-varney-ph-d-and-daniel-faga/ 2022-04-05T07:59:47-04:00 https://affinittx.com/a-new-biotech-startup-looks-to-sidestep-a-key-problem-with-car-t-cancer-therapies/ 2022-03-28T11:10:08-04:00 https://affinittx.com/juno-co-founder-launches-ambitious-new-startup-with-fred-hutch-colleagues-to-treat-cancer/ 2022-03-28T11:09:25-04:00 https://affinittx.com/new-cell-therapy-player-makes-public-debut-at-jpm/ 2022-03-28T11:08:33-04:00 https://affinittx.com/see-the-24-slide-pitch-deck-a-new-biotech-startup-just-used-to-raise-175-million-to-develop-the-next-cancer-breakthrough/ 2022-03-28T11:07:26-04:00 https://affinittx.com/vida-bayer-throw-weight-behind-175m-t-cell-startup/ 2022-03-28T11:05:30-04:00 https://affinittx.com/affini-t-therapeutics-launches-with-175-million-for-cancer-treatments/ 2022-03-28T11:02:59-04:00 https://affinittx.com/a-new-cell-therapy-startup-from-an-immunotherapy-pioneer-raises-175m-in-kras-quest/ 2022-03-28T11:00:57-04:00 https://affinittx.com/fred-hutch-spinout-affini-t-therapeutics-lands-175m-for-cell-therapies-to-treat-solid-tumors/ 2022-03-28T11:00:44-04:00 https://affinittx.com/bayer-backed-affini-t-snags-175m-to-enter-increasingly-crowded-kras-cancer-field/ 2022-03-28T11:00:08-04:00 https://affinittx.com/placeholder-text-for-press-release-announcement/ 2022-03-23T13:51:02-04:00 https://affinittx.com/affini-t-therapeutics-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference/ 2022-02-16T17:27:57-05:00